Clinical trial
An Open-label Study of the Safety and Tolerability of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
NCT03427151 is registered in ClinicalTrials.gov with ImmuPharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Study of the Safety and Tolerability of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
- Lead sponsor
- ImmuPharma
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 27, 2018
- Completion date
- February 5, 2019
- Enrollment
- 62 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.